Efficacy and Safety of Capecitabine Combined with Bevacizumab or Single Agent of Capecitabine as Maintenance Therapy for Advanced Colorectal Cancer

Jian-ping LI; Xue-ren GAO; Xiao-yan ZHANG; Ping CHEN; Su-rong CHEN; Wei-gang BIAN; Zhi-jun HUANG

doi:10.12259/j.issn.2095-610X.S20210908

Volume 42 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(9): 119-126

Jian-ping LI, Xue-ren GAO, Xiao-yan ZHANG, Ping CHEN, Su-rong CHEN, Wei-gang BIAN, Zhi-jun HUANG. Efficacy and Safety of Capecitabine Combined with Bevacizumab or Single Agent of Capecitabine as Maintenance Therapy for Advanced Colorectal Cancer[J]. Journal of Kunming Medical University, 2021, 42(9): 119-126. doi: 10.12259/j.issn.2095-610X.S20210908

Citation:

Jian-ping LI, Xue-ren GAO, Xiao-yan ZHANG, Ping CHEN, Su-rong CHEN, Wei-gang BIAN, Zhi-jun HUANG. Efficacy and Safety of Capecitabine Combined with Bevacizumab or Single Agent of Capecitabine as Maintenance Therapy for Advanced Colorectal Cancer[J]. Journal of Kunming Medical University, 2021, 42(9): 119-126. doi: 10.12259/j.issn.2095-610X.S20210908

Citation:

Jian-ping LI, Xue-ren GAO, Xiao-yan ZHANG, Ping CHEN, Su-rong CHEN, Wei-gang BIAN, Zhi-jun HUANG. Efficacy and Safety of Capecitabine Combined with Bevacizumab or Single Agent of Capecitabine as Maintenance Therapy for Advanced Colorectal Cancer[J]. Journal of Kunming Medical University, 2021, 42(9): 119-126. doi: 10.12259/j.issn.2095-610X.S20210908

PDF( 679 KB)

Efficacy and Safety of Capecitabine Combined with Bevacizumab or Single Agent of Capecitabine as Maintenance Therapy for Advanced Colorectal Cancer

doi: 10.12259/j.issn.2095-610X.S20210908

1.
Dept. of Oncology，The Yancheng Clinical College of Xuzhou Medical University，The First People’s Hospital of Yancheng，Yancheng Jiangsu 224006
2.
School of Pharmacy， Yancheng Teachers’ University，Yancheng Jiangsu 224007，China

Received Date: 2021-07-09
Available Online: 2021-09-13
Publish Date: 2021-09-30

Abstract

Abstract

Objective To investigate the efficacy and safety of capecitabine combined with bevacizumab or single agent of capecitabine as the maintenance therapy following the induction of XELOX regimen combined with bevacizumab in the first-line treatment of advanced colorectal cancer. Methods A total of 100 patients with the advanced colorectal cancer were treated with XELOX regimen （oxaliplatin plus capecitabine） combined with bevacizumab as first-line induction therapy for 6 cycles, whose efficacy were evaluated as the complete response, partial response or stable disease. These patients were divided in a 1∶1 ratio into the capecitabine combined with bevacizumab group （n = 50） and the single agent of capecitabine group （n = 50） for the maintenance therapy until the first disease progression or intolerable adverse events. The primary end point was progression-free survival from the initiation of maintenance therapy to the disease progression （PFS₁）. Secondary endpoints were progression-free survival from the initiation of induction therapy to the disease progression （PFS₂）, overall survival （OS） and adverse events. Results One-hundred patients were treated with capecitabine plus bevacizumab （n = 50） or single agent of capecitabine （n = 50） as the maintenance therapy. The median PFS₁, median PFS₂, and median OS of combination group were significantly longer than those of the monotherapy group, which were 9.0 （95% confidence interval （CI） 8.52-9.47） versus 7.2 （6.16-8.24, P < 0.0001） months, 13.5 （12.55-14.45） versus 12.3 （11.21-13.38, P < 0.0001） months and 27.0 （25.31-28.69） versus 26.2 （24.09-28.31, P = 0.011） months, respectively. Subgroup analysis showed that PFS₁ of the combination group was significantly prolonged in the simultaneous metastasis and RAS/BRAF mutant subgroups. OS of the combination group was significantly prolonged in the male and liver metastatic subgroups. Similar treatment-related adverse events were observed in both groups. The most common toxicities both were neutropenia, mucositis, hand-foot syndrome and diarrhea. The incidence of hypertension （20% versus 4%） and proteinuria （14% versus 2%） were higher in the combination group than that in the monotherapy group. Conclusion Both capecitabine combined with the bevacizumab and the single agent of capecitabine can be considered as the appropriate options following the induction of XELOX regimen combined with bevacizumab as the first line treatment for advanced colorectal cancer with good efficacy and acceptable toxicities. Capecitabine combined with bevacizumab as maintenance therapy has a better survival benefit than single agent of capecitabine.
- Advanced colorectal cancer,
- Induction therapy,
- Maintenance therapy,
- Bevacizumab,
- Capecitabine

FullText(HTML)

References(19)

References

[1]	Chen W,Zheng R,Baade P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132. doi: 10.3322/caac.21338
[2]	Arnold M,Sierra M S,Laversanne M,et al. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut.,2017,66(4):683-691. doi: 10.1136/gutjnl-2015-310912
[3]	Van Cutsem E,Nordlinger B,Adam R,et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases[J]. Eur J Cancer,2006,42(14):2212-2221. doi: 10.1016/j.ejca.2006.04.012
[4]	Luo H Y,Li Y H,Wang W,et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer:Randomized clinical trial of efficacy and safety[J]. Ann Oncol,2016,27(6):1074-1081. doi: 10.1093/annonc/mdw101
[5]	Geng R,Wang G,Qiu L,et al. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients[J]. Medicine (Baltimore),2020,99(51):e23719.
[6]	Simkens L H,van Tinteren H,May A,et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3):A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group[J]. Lancet,2015,385(9980):1843-1852. doi: 10.1016/S0140-6736(14)62004-3
[7]	Petrioli R,Francini E,Cherri S,et al. Capecitabine plus oxaliplatin and bevacizumab,followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer[J]. Clin Colorectal Cancer,2018,17(4):e663-e669. doi: 10.1016/j.clcc.2018.07.002
[8]	Nakayama G,Ishigure K,Yokoyama H,et al. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer:Amulti-center,single-arm,phase Ⅱ study (CCOG-0902)[J]. BMC Cancer,2017,17(1):243. doi: 10.1186/s12885-017-3245-1
[9]	Tournigand C,Cervantes A,Figer A,et al. OPTIMOX1:A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study[J]. J Clin Oncol,2006,24(3):394-400. doi: 10.1200/JCO.2005.03.0106
[10]	Chibaudel B,Maindrault-Goebel F,Lledo G,et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study[J]. J Clin Oncol,2009,27(34):5727-5733. doi: 10.1200/JCO.2009.23.4344
[11]	D í az-Rubio E,G ó mez-España A,Massutí B,et al. Spanish cooperative group for the treatment of digestive tumors. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer:The phase Ⅲ MACRO TTD study[J]. Oncologist,2012,17(1):15-25. doi: 10.1634/theoncologist.2011-0249
[12]	Matter-Walstra K,Schwenkglenks M,Betticher D,et al. Bevacizumab continuation versus treatment holidays after first-line chemotherapy with bevacizumab in patients with metastatic colorectal cancer:A health economic analysis of a randomized phase 3 trial (SAKK 41/06)[J]. Clin Colorectal Cancer,2016,15(4):314-320.e2. doi: 10.1016/j.clcc.2016.03.002
[13]	Aparicio T,Ghiringhelli F,Boige V,et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer:A randomized phase Ⅲ trial (PRODIGE 9)[J]. J Clin Oncol,2018,36(7):674-681. doi: 10.1200/JCO.2017.75.2931
[14]	Noepel-Duennebacke S,Arnold D,Hertel J,et al. Impact of the localization of the primary tumor and RAS/BRAF mutational status on maintenance strategies after first-line oxaliplatin,fluoropyrimidine,and bevacizumab in metastatic colorectal cancer:Results from the AIO 0207 Trial[J]. Clin Colorectal Cancer,2018,17(4):e733-e739. doi: 10.1016/j.clcc.2018.07.007
[15]	Aparicio T,Bennouna J,Le Malicot K,et al. Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval:Analysis from PRODIGE 9 trial[J]. Br J Cancer,2020,122(7):957-962. doi: 10.1038/s41416-020-0735-8
[16]	Loupakis F,Yang D,Yau L,et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer[J]. J Natl Cancer Inst,2015,107(3):dju427.
[17]	Manfredi S,Turpin A,Malka D,et al. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer:The bevamaint - prodige 71 -(FFCD 1710)phase Ⅲ study[J]. Dig Liver Dis,2020,52(10):1143-1147. doi: 10.1016/j.dld.2020.06.034
[18]	Sherman S K,Lange J J,Dahdaleh F S,et al. Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer[J]. JAMA Oncol,2019,5(2):236-242. doi: 10.1001/jamaoncol.2018.5070
[19]	Geng R,Wang G,Qiu L,et al. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients[J]. Medicine(Baltimore),2020,99(51):e23719.